TCM
ABBV icon

Telos Capital Management’s AbbVie ABBV Stock Holding History

Telos Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.63M Sell
18,380
-339
-2% -$72.9K 0.41% 76
2026
Q1 		$4.07M Sell
18,719
-371
-2% -$82.3K 0.39% 81
2025
Q4 		$4.36M Sell
19,090
-250
-1% -$57K 0.41% 78
2025
Q3 		$4.48M Sell
19,340
-536
-3% -$109K 0.43% 76
2025
Q2 		$3.69M Sell
19,876
-337
-2% -$62.6K 0.38% 81
2025
Q1 		$4.24M Sell
20,213
-2,738
-12% -$532K 0.46% 77
2024
Q4 		$4.08M Sell
22,951
-1,380
-6% -$254K 0.44% 78
2024
Q3 		$4.8M Sell
24,331
-642
-3% -$120K 0.5% 76
2024
Q2 		$4.28M Sell
24,973
-454
-2% -$75.2K 0.47% 76
2024
Q1 		$4.63M Sell
25,427
-25,808
-50% -$4.45M 0.52% 75
2023
Q4 		$7.94M Buy
51,235
+437
+0.9% +$63.7K 0.97% 34
2023
Q3 		$7.57M Buy
50,798
+900
+2% +$132K 1.05% 31
2023
Q2 		$6.72M Sell
49,898
-489
-1% -$71.7K 0.9% 35
2023
Q1 		$8.03M Sell
50,387
-3,952
-7% -$604K 1.12% 29
2022
Q4 		$8.78M Buy
54,339
+199
+0.4% +$30.5K 1.28% 21
2022
Q3 		$7.27M Buy
54,140
+164
+0.3% +$23.5K 1.2% 23
2022
Q2 		$8.27M Sell
53,976
-563
-1% -$86K 1.26% 19
2022
Q1 		$8.84M Sell
54,539
-1,765
-3% -$256K 1.15% 27
2021
Q4 		$7.62M Sell
56,304
-1,460
-3% -$172K 0.95% 35
2021
Q3 		$6.23M Sell
57,764
-14,997
-21% -$1.71M 0.85% 38
2021
Q2 		$8.2M Sell
72,761
-440
-0.6% -$49.6K 1.08% 29
2021
Q1 		$7.92M Buy
73,201
+33
+0% +$3.53K 1.14% 25
2020
Q4 		$7.84M Sell
73,168
-3,919
-5% -$377K 1.19% 25
2020
Q3 		$6.75M Sell
77,087
-462
-0.6% -$43.5K 1.18% 21
2020
Q2 		$7.61M Buy
77,549
+6,330
+9% +$557K 1.47% 18
2020
Q1 		$5.43M Buy
71,219
+48,658
+216% +$4.14M 1.34% 19
2019
Q4 		$2M Buy
22,561
+13,802
+158% +$1.15M 0.46% 75
2019
Q3 		$664K Buy
+8,759
New +$601K 0.18% 103

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Telos Capital Management's ABBV Position: Q2 2026 in Review

Telos Capital Management reduced its AbbVie (ABBV) stake by 1.8% in Q2 2026, selling an estimated $72.9K and leaving 18,380 shares worth $4.63M. The position accounts for 0.41% of the portfolio, ranked #76.

Telos Capital Management first reported a position in ABBV in Q3 2019 and has held it in 28 quarters since. The position peaked at $8.84M in Q1 2022. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Telos Capital Management held 18,380 shares of AbbVie worth $4.63M as of Q2 2026.
  • Telos Capital Management sold 339 AbbVie shares in Q2 2026, an estimated $72.9K.
  • AbbVie made up 0.41% of Telos Capital Management's portfolio in Q2 2026, its #76 holding.
  • Telos Capital Management first reported a position in AbbVie in Q3 2019 and has held it in 28 quarters since.
  • Telos Capital Management's AbbVie position peaked at $8.84M in Q1 2022.
  • 4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Telos Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.